Condition
Major Depression Severe
Total Trials
7
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (2)
P 2 (1)
Trial Status
Not Yet Recruiting3
Enrolling By Invitation1
Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07740694Recruiting
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
NCT07503002Phase 1Not Yet Recruiting
Shortened LSD Intervention for Major Depressive Disorder
NCT07683988Phase 1Not Yet RecruitingPrimary
Oral and Sublingual Ketamine
NCT07212946Phase 2CompletedPrimary
Ayahuasca and Esketamine for Major Depression
NCT07146269Not ApplicableEnrolling By Invitation
Virtual Reality-Augmented At-Home tDCS for Major Depression
NCT06748950Not ApplicableNot Yet Recruiting
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
NCT03254342Terminated
MRS and Medication Response: A Pilot Study
Showing all 7 trials